Icon times
Muted performance in US and Ex-US generics and one-off write-off of Aleor's Intangible assets, tumbles sales and profit | Alembic Pharmaceuticals Q1 FY23 Result & Earning Call Highlights

Muted performance in US and Ex-US generics and one-off write-off of Aleor's Intangible assets, tumbles sales and profit | Alembic Pharmaceuticals Q1 FY23 Result & Earning Call Highlights

Published on 08 August 2022 .Views 6 .Comments 0
Attachments:
private article suscription area icon

You like to know more. We like that!

Please subscribe Model Portfolio Plan to get access of all premium model portfolio articles Only at Rs. 11,999.00/Year.

Please login to view this free article.

This blog is available only for logged in users, please register and get access to view this article.

Recently Uploaded


premium Premium
free Free
Chat on WhatsApp
Caret UP Arrow
InvestYadnya Support
Typically replies in minutes
InvestYadnya Support
Hi there
Welcome to InvestYadnya.
We are available to assist you on WhatsApp.
Please click on the button below to chat with us.
(10 AM to 7 PM IST)
16:10
Chat with InvestYadnya